A metabolomic perspective of melatonin metabolism in the mouse

被引:46
作者
Ma, Xiaochao [1 ]
Chen, Chi [1 ]
Krausz, Kristopher W. [1 ]
Idle, Jeffrey R. [2 ]
Gonzalez, Frank J. [1 ]
机构
[1] NCI, Lab Metab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA
[2] Charles Univ Prague, Fac Med 1, Inst Pharmacol, Prague 12800, Czech Republic
关键词
D O I
10.1210/en.2007-1412
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Metabolism of melatonin (MEL) in mouse was evaluated through a metabolomic analysis of urine samples from control and MEL-treated mice. Besides identifying seven known MEL metabolites (6-hydroxymelatonin glucuronide, 6-hydroxymelatonin sulfate, N-acetylserotonin glucuronide, N-acetylserotonin sulfate, 6-hydroxymelatonin, 2-oxomelatonin, 3-hydroxymelatonin), principal components analysis of urinary metabolomes also uncovered seven new MEL metabolites, including MEL glucuronide, cyclic MEL, cyclic N-acetylserotonin glucuronide, cyclic 6-hydroxymelatonin; 5-hydroxyindole-3-acetaldehyde, di-hydroxymelatonin and its glucuronide conjugate. However, N-1-acetyl-N-2-formyl-5-methoxy-kynuramine and N-1-acetyl-(5)-methoxy-kynuramine, known as MEL antioxidant products, were not detected in mouse urine. Metabolite profiling of MEL further indicated that 6-hydroxymelatonin glucuronide was the most abundant MEL metabolite in mouse urine, which comprised 75, 65, and 88% of the total MEL metabolites in CBA, C57/BL6, and 129Sv mice, respectively. Chemical identity of 6-hydroxymelatonin glucuronide was confirmed by deconjugation reactions using beta-glucuronidase and sulfatase. Compared with wild-type and CYP1A2-humanized mice, Cyp1a2-null mice yielded much less 6-hydroxymelatonin glucuronide (similar to 10%) but more N-acetylserotonin glucuronide (similar to 195%) and MEL glucuronide (similar to 220%) in urine. In summary, MEL metabolism in mouse was recharacterized by using a metabolomic approach, and the MEL metabolic map was extended to include seven known and seven novel pathways. This study also confirmed that 6-hydroxymelatonin glucuronide was the major MEL metabolite in the mouse, and suggested that there was no interspecies difference between humans and mice with regard to CYP1A2-mediated metabolism of MEL, but a significant difference in phase II conjugation, yielding 6-hydroxymelatonin glucuronide in the mouse and 6-hydroxymelatonin sulfate in humans.
引用
收藏
页码:1869 / 1879
页数:11
相关论文
共 40 条
[1]   Melatonin: structural characterization of its non-enzymatic mono-oxygenate metabolite [J].
Agozzino, P ;
Avellone, G ;
Bongiorno, D ;
Ceraulo, L ;
Filizzola, F ;
Natoli, MC ;
Livrea, MA ;
Tesoriere, L .
JOURNAL OF PINEAL RESEARCH, 2003, 35 (04) :269-275
[2]   Effects of exogenous melatonin - A review [J].
Anisimov, VN .
TOXICOLOGIC PATHOLOGY, 2003, 31 (06) :589-603
[3]   DNA oxidatively damaged by chromium(III) and H2O2 is protected by the antioxidants melatonin, N1-acetyl-N2-formyl-5-methoxykynuramine, resveratrol and uric acid [J].
Burkhardt, S ;
Reiter, RJ ;
Tan, DX ;
Hardeland, R ;
Cabrera, J ;
Karbownik, M .
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2001, 33 (08) :775-783
[4]  
Buscemi N, 2004, Evid Rep Technol Assess (Summ), P1
[5]   Urinary metabolite profiling reveals CYP1A2-mediated metabolism of NSC686288 (aminoflavone) [J].
Chen, Chi ;
Meng, Linghua ;
Ma, Xiaochao ;
Krausz, Kristopher W. ;
Pommier, Yves ;
Idle, Jeffrey R. ;
Gonzalez, Frank J. .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2006, 318 (03) :1330-1342
[6]   Differential metabolism of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in mice humanized for CYP1A1 and CYP1A2 [J].
Cheung, C ;
Ma, XC ;
Krausz, KW ;
Kimura, S ;
Feigenbaum, L ;
Dalton, TP ;
Nebert, DW ;
Idle, JR ;
Gonzalez, FJ .
CHEMICAL RESEARCH IN TOXICOLOGY, 2005, 18 (09) :1471-1478
[7]  
de Almeida EA, 2003, J PINEAL RES, V35, P131
[8]  
Dubois G, 1976, Adv Exp Med Biol, V68, P233
[9]   GENETIC-CONTROL OF MELATONIN SYNTHESIS IN THE PINEAL-GLAND OF THE MOUSE [J].
EBIHARA, S ;
MARKS, T ;
HUDSON, DJ ;
MENAKER, M .
SCIENCE, 1986, 231 (4737) :491-493
[10]   HUMAN HEPATOCYTES AS A KEY INVITRO MODEL TO IMPROVE PRECLINICAL DRUG DEVELOPMENT [J].
FABRE, G ;
COMBALBERT, J ;
BERGER, Y ;
CANO, JP .
EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 1990, 15 (02) :165-171